Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Dry and eczema-prone skin conditions such as atopic dermatitis and xerotic eczema primarily indicate an impaired skin barrier function, which leads to chronic pruritus. Here, we investigated the effects of a novel emollient containing H.ECM liposome, which contains a soluble proteoglycan in combination with hydrolyzed collagen and hyaluronic acid. A prospective, single-arm study was conducted on 25 participants with mild atopic dermatitis or dry skin to assess the hydration and anti-inflammatory effect of the novel emollient applied daily over four weeks. All efficacy parameters, including itching severity, transepidermal water loss, and skin hydration, improved significantly after four weeks. The in vitro and ex vivo studies confirmed the restoration of the skin's barrier function. The study revealed the clinical and laboratory efficacy of H.ECM liposome in reducing itching and improving the skin's barrier integrity. Thus, the use of H.ECM liposome can be considered a therapeutic option for dry and eczema-prone skin.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508667PMC
http://dx.doi.org/10.3390/ijms221910189DOI Listing

Publication Analysis

Top Keywords

atopic dermatitis
12
dry eczema-prone
12
eczema-prone skin
12
hecm liposome
12
hyaluronic acid
8
hydrolyzed collagen
8
skin barrier
8
mild atopic
8
dermatitis dry
8
barrier function
8

Similar Publications

Allergic diseases, characterized by complex pathological mechanisms involving immune dysregulation and chronic inflammation, impose a substantial burden on global health. The Hippo signaling pathway, a highly conserved regulator of cell proliferation, apoptosis, immune homeostasis, and tissue repair, has recently emerged as a pivotal player in allergic disease pathogenesis. This review synthesizes current knowledge on the core components and physiological functions of the Hippo pathway, elucidates its mechanistic roles in major allergic disorders-including allergic asthma, allergic rhinitis, atopic dermatitis, and food allergies-and evaluates the therapeutic potential of targeting this pathway.

View Article and Find Full Text PDF

The interaction between the skin microbiome and antimicrobial peptides within the epidermal immune microenvironment: Bridging insights into atopic dermatitis.

Allergol Int

September 2025

Atopy (Allergy) Research Center, Juntendo University Graduate School of Medicine, Tokyo, Japan; Faculty of International Liberal Arts, Juntendo University, Tokyo, Japan. Electronic address:

The epidermal immune microenvironment is a multifaceted system in which the interplay between the skin microbiome and antimicrobial peptides plays a pivotal role in sustaining skin homeostasis and preventing dysbiosis. Disruption of these interactions can lead to inflammatory skin conditions such as atopic dermatitis. This review aims to explore the complex mechanisms by which antimicrobial peptides and the skin microbiome communicate within the epidermal immune microenvironment, emphasizing causal dynamics and the dual role of antimicrobial peptides.

View Article and Find Full Text PDF

Relationship between CFTR variants, sweat chloride responses, and lung function improvements.

Lancet Respir Med

September 2025

Department for Paediatric Pneumology, Allergology, and Neonatology and German Center for Lung Research, Biomedical Research in Endstage and Obstructive Lung Disease, Hannover Medical School, 30625 Hannover, Germany. Electronic address:

View Article and Find Full Text PDF

Targeting PAR-2 in atopic dermatitis: Preclinical evaluation of the novel inhibitor E6795.

Biochem Biophys Res Commun

September 2025

Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan; A∗STAR Skin Research Labs (A∗SRL), Skin Research Institute of Singapore (SRIS), Singapore Immunology Network (SIgN), Agency for Science, Technology, and Research (A∗STAR), 8A Biomedical Grove, IMMUNOS Buildi

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by eczematous lesions, intense itching, and compromised skin barrier function. Despite the advent of new therapeutics, many individuals still face insufficient disease control, high costs, and relapse. Protease-activated receptor 2 (PAR-2), overexpressed in AD lesions, plays a central role in promoting inflammation, itch, and alterations in epidermal homeostasis.

View Article and Find Full Text PDF